GLP-1s in Cardiovascular-Kidney-Metabolic Syndrome: Going Beyond Weight Loss and Glycemic Control
Speaker Information
Rachel Bassett Allen, PharmD, CPP, BCACP
Clinical Pharmacist
Duke University Hospital
Learning Objectives:
Define cardiovascular-kidney-metabolic (CKM) syndrome, including risk factors and staging criteria
Describe guideline-directed management strategies for CKM syndrome
Review key clinical trials of incretin therapies in chronic kidney disease, cardiovascular disease, heart failure, and additional metabolic risk factors
Description:
GLP-1 receptor agonists have emerged as key therapies in cardiovascular-kidney-metabolic (CKM) syndrome, with benefits extending beyond weight loss and glycemic control. This session will review the evolving evidence supporting their use in obesity, cardiovascular disease, chronic kidney disease, and additional metabolic risk factors. Pharmacists and pharmacy technicians will gain practical insights into patient selection, guideline-directed therapy, and strategies to optimize care across the CKM disease continuum.
Members: FREE Non-Members: $25.00
Date:Sunday, December 13 Time: 6:00 - 7:00PM
Accredited for Pharmacists and Technicians: 1.0 Hour of ACPE Continuing Education